Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest IMS Health Stories

2013-09-23 12:26:17

Inks Strategic Agreement to Promote Locoid® Lotion to US Pediatricians MUMBAI, India and BALTIMORE, September 23, 2013 /PRNewswire/ -- Pharmaceutical Major, Lupin Ltd. and its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) announced today that it has signed a strategic co-promotion agreement with US based Onset Dermatologics, LLC ("Onset") that grants Lupin exclusive rights to promote Onset's Locoid(R) Lotion (hydrocortisone butyrate 0.1%) to Pediatricians in...

2013-09-16 08:28:38

PARSIPPANY, N.J., Sept. 16, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has launched a generic version of Lidoderm(®) (lidocaine topical patch 5%), as part of an exclusive settlement agreement with Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd. Actavis has begun shipping the product and believes that, under applicable Hatch Waxman rules, it is entitled to 180 days of marketing exclusivity. Lidoderm(®) is a local anesthetic indicated to relieve...

2013-09-12 16:24:52

CAMBRIDGE, Mass., Sept. 12, 2013 /PRNewswire/ -- HawkPartners, LLC is pleased to announce that Margie Sherr has joined the firm as a Partner. Margie brings a wealth of experience helping healthcare clients research, develop, and implement marketing strategies, continuing to strengthen HawkPartners' capabilities in this evolving industry area. Margie will be working out of the Philadelphia area but serving clients around the country. (Logo:...

2013-09-10 12:29:52

YEHUD, Israel, September 10, 2013 /PRNewswire/ -- Treato [http://treato.com ], the source of "patient voice" intelligence from across the social web, today announced the new version of its flagship Treato Pharma platform for pharmaceutical companies and agencies. Treato's proprietary big data technology platform extracts real-time patient insights about drugs, conditions and treatments from over 1.5 billion health-related discussions posted on thousands of blogs, forums...

2013-09-06 23:20:23

The imaging center market contracted 3.65% in 2013, following a sharp 35% decline in imaging center volumes in 2011, according to a report from Radiology Business Journal and IMS Health. Irvine & Tustin, CA (PRWEB) September 06, 2013 Pressure on reimbursement and increased competition took their toll on the imaging-center market in 2013 with the first reported declines on record in inventory, per-center volumes, and annual visits, according to a report on the Top 20 Imaging Center...

2013-07-26 08:25:16

-Expects to be eligible for 180 days of marketing exclusivity- PITTSBURGH, July 26, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued by Eisai Co., Ltd., Eisai Inc., and Novartis Pharma AG in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Rufinamide Tablets, 200 mg and 400 mg. This product is the generic version of BANZEL(®), which is indicated for the...

2013-07-24 08:29:48

PITTSBURGH, July 24, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg. This product is the generic version of TARCEVA(®), and is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or...

2013-07-16 12:27:59

PITTSBURGH, July 16, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Norethindrone Tablets USP, 0.35 mg. Norethindrone Tablets USP, 0.35 mg, are the generic version of Watson Laboratories' (now Actavis, Inc.) Nor-Q.D.® Tablets, 0.35 mg (28-Day Cycle), which are indicated for the prevention of pregnancy. Mylan's partner, Famy Care Ltd., received final approval from the U.S. Food and Drug...

2013-07-15 12:25:18

PITTSBURGH, July 15, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg. Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg, are the generic version of Abbott's Trilipix® Capsules, which are indicated as an adjunct to diet in combination with a statin to reduce triglyceride and increase high-density lipoprotein cholesterol in...

2013-07-15 08:26:56

-Expects to be eligible for 180 days of marketing exclusivity- PITTSBURGH, July 15, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued by UCB, Inc., UCB Pharma GMBH, Research Corporation Technologies, Inc. and Harris FRC Corporation in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg. This product is the generic...